MedTrace Logo

Tenapanor in Synucleinopathy-Related Constipation

NCT06460038 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-02-10

No results posted yet for this study

Summary

Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation

Conditions

Interventions

DRUG

Tenapanor

Inhibitor of NHE3

DRUG

Placebo

Placebo drug

Sponsors & Collaborators

  • Ardelyx

    collaborator INDUSTRY

  • Cedar Valley Digestive Health Center

    lead OTHER

Principal Investigators

  • Richard A. Manfready, MD, AM, FACP · Cedar Valley Digestive Health Center

  • Ravindra Mallavarapu, MD · Cedar Valley Digestive Health Center

  • Harichandana Punukula, PharmD, MS · Cedar Valley Digestive Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-12-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06460038 on ClinicalTrials.gov